Annual Report

The report describes a strong 2025 performance for the company, with consolidated net revenue of EUR 2,618.4 million and continued growth across Specialty & Primary Care and Rare Diseases. It highlights the completion of solar installations in Tunisia and Italy and the expansion in Spain, bringing installed power to approximately 6,200 kWp. The company also reports a target to reduce Scope 1 and Scope 2 market-based emissions by 20% by 2030 against a 2022 base year. Workforce initiatives included D&I training for approximately 95% of employees and a year-end employee total of 4,693.